Finding Specialists and Paying for Services
- Introduction to Clinical Trials
- Research Findings
- Studies Enrolling Patients
- Research Collaborations
NCT01116648
Cediranib and Olaparibin Combination for Recurrent Ovarian or Triple-Negative Breast Cancer
Study identifier: NCT01116648
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Olaparib (AstraZeneca)
Eligibility:
Study for women with stage IV (metastatic) triple negative breast cancer. Breast cancer patients must have already received and recurred after both adriamycin-and taxane-containing chemotherapy and have had at least 1 chemotherapy for metastatic breast cancer.
Type of study:
Phase I study
Treatment:
Breast cancer patients who enroll will receive both cediranib and olaparib.
Study site:
Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
Contact: Joyce Liu, MD 617-632-5269
Contact: Christen Whalen christin_whalen@dfci.harvard.edu
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.